Stock comparison
LeMaitre Vascular
Anbio Biotechnology
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.27B
Sector
Healthcare
NNNN
Anbio Biotechnology
Market cap
$1.43B
Sector
Healthcare
Overall winner
Anbio Biotechnology NNNN
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | NNNN | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 58C | LMAT |
| Benjamin Graham | 89A | 87A | LMAT |
| Philip Fisher | 81C | 89A | NNNN |
| Peter Lynch | 67B | 95A | NNNN |
| Joel Greenblatt | 56D | 36D | LMAT |
| Charlie Munger | 68D | 73C | NNNN |
| Terry Smith | 69D | 72C | NNNN |
Side-by-side metrics
| Metric | LMAT | NNNN |
|---|---|---|
| Market cap | $2.27B | $1.43B |
| P/E (TTM) | 37.1x | 171.9x |
| EV/EBIT | 36.6x | 212.9x |
| ROIC (TTM) | 9.43% | 21.48% |
| Gross margin | 72.39% | 87.06% |
| Net margin | 24.35% | 73.75% |
| Revenue CAGR 5y | 12.75% | 18.21% |
| EPS CAGR 5y | 19.04% | 58.42% |
| Debt / Equity | 0.5x | - |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- EV/EBIT36.6xvs 212.9x+83%
- P/E (TTM)37.1xvs 171.9x+78%
- Market cap$2.27Bvs $1.43B+37%
NNNN leads on
- Debt / Equity-vs 0.5x+100%
- EPS CAGR 5y58.42%vs 19.04%+67%
- Net margin73.75%vs 24.35%+67%
- ROIC (TTM)21.48%vs 9.43%+56%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.